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We report here a case of acute lymphoblastic leukemia in remission presenting a late-onset bilateral hydronephrosis probably due
to polyoma BK virus-induced proliferation of bladder endothelium on both ostii. The diagnosis was made virologically by BK
virus Polymerase Chain Reaction (PCR) detection in the absence of any other bladder disease. Awareness of this late complication
is necessary not only in patients after renal transplantation but also in patients after hematopoietic stem cell transplantation from
matched unrelated donor.
1.Introduction
Polyomavirus BK was ﬁrst isolated 1971 from the urine of an
asymptomatic renal transplant patient who was hospitalized
with acute renal injury and with initials BK [1]. It is a
deoxyribonucleic acid (DNA) virus with circular double-
stranded DNA genome and a nonenveloped icosahedral
capsid [2]. Primary infection with BK virus usually occurred
in childhood and was generally asymptomatic. After primary
infection, BK virus entered a latent state and resided in
uroepitel cells [3]. More than 80 percent of adults had
serologic evidence of infection [3]. In immunocompromised
hosts, such as renal transplant patients, BK virus may
reactivate and cause hemorrhagic cystitis and severe allograft
dysfunction with acute tubulointerstitial nephritis [4, 5].
BK viruria has been associated with a variety of clinical
manifestations, mostly with hemorrhagic cystitis, being
associated with signiﬁcant morbidity and mortality [6, 7].
Importantly, BK virus infection could escalate from viruria
to viremia to nephropathy [8]. BK nephropathy began as a
localized viral presence in the tubular epithelial cells of the
kidney and progressed to a diﬀuse and destructive T-cell-
mediated interstitial nephritis [9].
About 50% of patients after hematopoietic bone marrow
transplantation presented with BK viruria, usually within 2
months of transplantation [10, 11], with similar incidence in
both autologous and allogenic recipients (39–54%) [12].
2.CaseReport
A 18-year-old patient with a history of Matched-Unrelated-
Donor Peripheral Blood Stem Cell Transplantation (MUD-
PBSCT)wasadmittedtothehospitalbecauseofrenalfailure.
In November 2007 the patient was ﬁrst diagnosed with
acute lymphoblastic leukemia of T cells (T-ALL) at another
institution, where he was treated with induction therapy
according to Hyper-CVAD Protocol (Cyclophosphamide
300mg/m2 intravenously (IV) over 3 hours every 12 hours
for six doses on days 1 through 3, with mesna given
by continuous infusion, vincristine 2mg IV days 4 and
11, doxorubicin 50mg/m2 IV day 4, and dexamethasone
40mg daily on days 1 through 4 and 11 through 14)2 Journal of Transplantation
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Figure 1: BK virus (BKV) levels in a patient after MUD-PBSCT.
Brocken lines indicate BKV in plasma and diamonds serum
creatinine level. Horizontal arrows indicate changes in the antiviral
therapy.
and was refractory when he presented in our department
of hematology/oncology [13]. The diagnosis of T-ALL
has been conﬁrmed, immunophenotype precursor T-ALL
(CD7, CD3, CD2, CD4, and CD8 pos), cytogenetic 46,
XY, Fluorescein in sito hybridisation (FISH) analysis 87%
deletion of p16 on the chromosome 9 region p21. He
was then treated with induction therapy according to the
German multicenter ALL protocol (GMALL) achieving only
reduction of blasts after Induction II. Brieﬂy, the induction
in GMALL protocol was composed of eight cytotoxic drugs
administered sequentially in two phases over an 8-week
period. During the ﬁrst 4 weeks (phase I), the patient
received 60mg/m2 prednisolone PO daily (days 1 through
28) plus 45mg/m2 daunorubicin and 2mg vincristine IV
weekly (days 1, 8, 15, and 22). L-asparaginase (5 000U/m2)
was administered IV daily (days 15 through 28). In the
second 4 weeks (phase II), the patient received two doses
of 650mg/m2 cyclophosphamide IV (days 29, 43, and 57)
together with 60mg/m2 6-mercaptopurine PO daily (days
29 through 57) and four courses of 75mg/m2 cytarabine IV
(days 31 through 34, 38 through 41, 45 through 48, and 52
through 55) [14]. He was then treated with nelarabine and
achieved complete remission (CR1) following MUD-PBSCT.
The conditioning consisted of total body irradiation (TBI),
12Gy, given fractionated 2 times daily for three days, from
day −6t od a y−4, and cyclophosphamide 60mg/kg once
daily i.v. on days −3a n d−2 (total dose 120mg/kg b.w.).
A Human Leukocyte Antigen (HLA) identical unrelated
donor peripheral blood stem cells were infused on day 0.
Graft-versus-Host Disease (GvHD) prophylaxis consisted of
thymoglobulin (2mg/kg b.w. daily, from day −3t o−1, total
dose of 6mg/kg b.w.), cyclosporine 5mg/kg starting on day
−1, and methotrexate at days +1, +3, +6, and +11 intra-
venously 15mg absolute. The bone marrow puncture on day
+28 showed a complete hematological remission with 100%
donor chimerism. Along with the regeneration of white
blood cells the patient developed a methylprednisolone-
dependent GvHD of the skin and gastrointestinal, grade
II. After 10 days the therapy with corticosteroids could
be discontinued by rapid improvement of the GvHD-
related symptoms. Under the therapy with corticosteroids
the patient developed a herpes simplex related oesophagitis
on day 21 post transplant which was treated with 30g daily
over 5 days i.v. immunoglobulin and foscarnet 90mg/kg b.w.
divided in 2 doses. On day +28 after PBSCT the patient
developed a hemorrhagic cystitis with high urine titers of
BK polyoma virus and CMV infection. A therapy with
ganciclovir was initiated for ten days. Under treatment with
ganciclovir, CMV infection improved, and the treatment
with cidofovir was started (1mg/kg b.w. for two weeks).
The BK Virus viruria and viremia improved, and the patient
received ganciclovir treatment for additional two weeks
(Figure 1). The cyclosporine level was from 200 to 150
from day 0 to day 30, followed with level of 100 from day
30 to day 40 post transplant, and level of 50 from day
40 to day 50. The cyclosporine has been discontinued on
day +70 after MUD-PBSCT in absence of acute GvHD and
as recommended in GMALL protocol. On day +48 after
PBSCT a cystoscopy with a continuous intravesical saline
irrigation was started and discontinued 2 weeks later. The
patient symptoms improved, and creatinine levels returned
to normal. He was discharged from hospital; his medications
at the time of discharge included ciproﬂoxacin (250mg twice
daily),valacyclovir(500mgtwicedaily),ﬂuconazole(200mg
daily),folate,andcotrimoxazoletwiceweeklyforprophylaxis
of pneumocystis carinii infection.
Over the next year the levels of urea nitrogen and
creatinine gradually rose (Table 1), which was attributed
to drug toxicity. cotrimoxazole prophylaxis was stopped.
Cyclosporine was discontinued since no signs of GvHD
were present 6 months after PBSCT. The serum creatinine
level was 153µmol/l (Table 1). Routine urinary diagnostic
measures were carried out and showed inconsistent micro-
hematuria. BK viruria was negative in this period.
On admission, blood pressure was 130/80mmHg with
90 heart beats per minute, a temperature of 36.4◦C, and an
oxygen saturation of 99% when the patient was breathing
ambientair.Thelungswereclear,theresultsoftheremainder
of the examination were normal. The complete blood count
and levels of serum electrolytes, liver function tests, and
levels of total protein and albumin were normal. The urine
sediment was not nephritic but contained a small amount
of leukocytes indicating an inﬂammatory process such as
cystitis. Results of other laboratory tests are shown in
Table 1.
Ultrasonographic examination of the kidneys showed
bilateral hydronephrosis stage III-IV (Figure 2(a)). In addi-
tion, decreased echotexture bladder tumours were seen
(Figure 2(b)). The patient was presented to the urologist.
Cystoscopywithurethrographyhasshownexophyticbladder
tumours in both ostii. The extirpation of the tumours
was performed and sent oﬀ for pathological examina-
tion. In addition a double-J catheter was placed. The
hydronephrosis of the left kidney improved immediatelyJournal of Transplantation 3
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Figure 2: Ultrasound examination of the right kidney and the bladder on admission. Hydronephrosis stage III-IV with severely reduced
renal parenchyma (a) and bladder tumorous formation (b).
Table 1: Results of laboratory tests.
Variable Reference range
in adults∗
Before
MUD-PBSCT
1m o n t ha f t e r
MUD-PBSCT
6 months after
MUD-PBSCT On admission 1 year later
Urea nitrogen (mmol/l) 3.8–8.0 6.9 33.3 5.8 21.7 12
Creatinine (µmol/l) 62–106 64 233 153 299 150
Cyclosporine (ng/ml) 128
eGFR (MDRD; ml/min) >90# 137# 31 50 23 51
24-Hr urine collection
Total Volume (ml) 2650 6650 3200 4200
Creatinine (mg/ml) 3865 1378 5660 2812
Total Protein (mg/24h) 0–135 Negative 1390 Negative 382 Negative
∗The ranges used at University Hospital Leipzig are for adults who are not pregnant and do not have medical conditions that could aﬀect the results.
This is only for visualization. The eGFR MDRD formula has not been validated outside the 20 to 60ml/min range.
and improved to grade II in the right kidney. For histo-
logical examination tissues were formalin-ﬁxed overnight
and embedded in paraﬃn. Hematoxylin & Eosin staining
of 5 micrometer sections was performed following standard
procedures.
The pathohistology of the specimen showed a chronic
cystical urocystitis with bleedings (Figure 3(a)). Tissue
probes of both ureters were stained for SV40 large T
antigen (clone pAb416, Oncogene Science, Boston, Mass,
USA; dilution 1:100, antigen retrieval and ampliﬁcation
with catalyzed system ampliﬁcation, Dako, Carpinteria, CA).
The reactions were detected by means of the streptavidin-
biotin method and were revealed using diaminobenzidine
as a chromogen [15, 16] .I na l lt i s s u ep r o b e si m m u n o h i s t o -
chemistry for large T antigen was negative (Figure 3(b)).
The patient has undergone double-J catheter controls
and changes every two months and is doing well 2 years after
PBSCT and 1 year after operative extirpation of tumours.
The last control was in April 2010 (Table 1).
3.Detectionof BKVirusby RealTime PCR
Two diﬀerent regions of the BKV genome were ampliﬁed
by PCR, VP2 in serum and urine, and large T antigen from
tissue biopsies.
Nucleicacidswereextractedfrom200microliterbloodor
urine using magnetic beads (MagNA Pure LC total NA isola-
tionkit,Roche,Mannheim,Germany)accordingtotheman-
ufacturer’s instructions while from formalin-ﬁxed, paraﬃn-
embedded material nucleic acids were extracted using the
QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany).
VP2 primers lead to ampliﬁcation of a 131bp fragment [17].
PCRreactionwascarriedoutin20microlitercapillariescon-
taining master mix (6mM MgCl2, 0.1mg/ml BSA (Sigma,
St. Louis, USA)) and 10 picoM of each primer (Metabion,
Martinsried, Germany), 3 picoM of each hybridization
probe (5
 -GGCTGCTGCTGCCACAGGATTTTC-FL (probe
1)and5
 LCRed640-GTAGCTGAAATTGCTGCTGGAGAG-
ph (probe 2), 0.25mM dNTP’s (Roche)), and 1U Platinum4 Journal of Transplantation
(a) (b)
Figure 3: Urothelial mucosa with erosions, edema, fresh bleedings, and bleeding residues. Moderate inﬂammatory reaction (a).
Immunohistochemically, large T antigen could not be visualized (b) ((a) magniﬁcation ×100, (b) magniﬁcation ×400).
Taq Polymerase (Invitrogen, Karlsruhe, Germany). Target
DNA was added in a volume of 5 microliters. Two neg-
ative and 4 positive controls in diﬀerent concentrations
were included into each run performed on a LightCycler
1.0 instrument (Roche, Mannheim, Germany) under the
following conditions: initial denaturation and activation of
hot-start enzyme at 95◦C for 30s, followed by 45 cycles
of denaturation at 95◦C for 0s, annealing of primers at
58◦Cf o r1 0 s ,a n dp r i m e re x t e n s i o na t7 2 ◦Cf o r2 0 s .
Fluorescence was monitored by single acquisition during the
annealing phase of each PCR cycle and channel setting F2/F1
(640nm/530nm). Diﬀerentiation of BK virus amplicons
from JC virus depends on the binding of the probe 2, which
perfectly matches JC virus but diﬀers at the two underlined
positions from BK virus. Thus binding to BK virus results
in a shifted melting curve (61.5◦C for BK versus 63.8◦Cf o r
JC).
For detection of the viral large T-antigen, a 128bp long
fragment was ampliﬁed using modiﬁed primers from [18]
that match BKV genotypes 1 to 4, forward primer 5 -
CAGGCAAGGGTTCTATTACTAAAT-3 , reverse primer 5 -
GCAACAGCAGATTCYCAACA-3 ,p r o b e5  -6FAM-AAA-
CTGGTGTAGATCAGARGGAAAGTCTTTAGGGTCTT-
BBQ.
PCRconditionswereidenticaltotheonedescribedabove
except TaqMan probe that was used at 4 pico molar, primer
annealingwas56◦Cfor10s,andﬂuorescenceacquisitionwas
at the end of each primer extension phase at 530nm.
4. Discussion
WedescribedayoungpatientwithprecursorT-ALLwhohad
received an unrelated matched donor PBSCT and one year
later presented with increase creatinine levels and bilateral
hydronephrosis.
Nephrological and urological examination showed an
epithelialproliferationofbladderonbothostiibeingrespon-
sible for bilateral hydronephrosis. Further pathological and
molecular analysis revealed widespread endothelial infection
by a BK virus. We speculate that the endothelial cell injury
led to capillary injury, oedema, and tumorous proliferation
on both ostii. Other organs were not involved.
This case demonstrated a very late (one year after MUD-
HSCT) proliferative endothelial infection by a virus related
to severe viral load and hemorrhagic cystitis 4 weeks after
unrelated PBSCT. Although the tumour mass could not
be unambiguously attributed to BKV since the staining
of large T antigen was negative in immunohistochemical
analysis, large T-cell antigen and BK virus were positive
by PCR, thus supporting the view that BK virus may
indeed play a role in the development of this tumour. The
oncogenic potential of BK virus has been well recognized
[2, 3]; Geetha et al. reported the case of a simultaneous
pancreas and kidney transplant recipient who developed
BKV interstitial nephritis and carcinoma of the bladder with
widespread metastasis. For both the primary tumour and the
metastasis, immunohistochemical staining for the large T-
cell antigen showed strong nuclear positivity [19]. However,
the diagnosis of the role of BK virus infection as a transient
“hit and run” agent is according to Hirsch [20]d i ﬃcult to
prove with the current diagnostic tools.
BK virus is an important pathogen and cause of
nephropathy in renal transplant recipients, but its signif-
icance following PBSCT is less well described. Recently,
O’Donnell et al. have shown in 124 allogeneic PBSCT
patients that BK viruria was manifest in 65% of the patients;
17% of the patients developed viremia. The median time
from transplantation to BK viremia development was 128
days and was longer for viruria (24 days) [21]. Among clini-
cal factorssuch as sex, disease, transplant type, alemtuzumab
use, cytomegalovirus viremia, graft-versus-host disease, andJournal of Transplantation 5
donor HLA C7 allele, only CMV viremia was more common
in patients with BK virus infection. In addition, BK virus
infection was analysed with other clinical factors related
to the development of post-PBSCT renal impairment. On
multivariate analysis, only BK viremia and alternative donor
transplantationwereindependentpredictorsofdevelopment
of post-HSCT renal impairment [21]. There are numerous
papers showing that there is no association between CMV
and BKV reactivation. One of the best examples is by Hirsch
et al., 2002 NEJM, where no CMV prophylaxis was given
and only CMV seropositive and BKV seropositive kidney
recipients were examined [22]. Harkensee et al. published
the results on the incidence of BK virus in 102 children
who underwent allogeneic HSCT [23]. BK virus DNA was
detected in the urine of 47% children; the only signiﬁcant
factor for hemorrhagic cystitis was high-dose chemotherapy.
The treatment included the use of cidofovir, which was
feasible and without signiﬁcant toxicity [23]. The evidence-
based guidelines for clinical management include in addition
to virus-speciﬁc therapy the use of estrogen or bladder
instillation with alum salts or prostaglandin, as recently
reviewed [24–26].
The chronic renal failure was a multifactorial process.
The transforming potential of BK virus infection has been
noted early both in vitro culture models and in vivo.
One of the patients with BK virus-associated nephropathy
after kidney transplantation reported by Vats et al. [26]
presented with an echogenic renal mass that resolved with
immunosuppressionreductionandtreatmentwithcidofovir.
Contributing factors included drug toxicity around PBSCT
(cyclosporine in particular), polyoma BK viruria, although
it was not proven whether the kidneys were involved, and
chronic hydronephrosis along with an inﬂammatory process
due to the urine congestion.
In summary, we could show an unusual case of late
onset of bilateral hydronephrosis probably due to BK virus-
induced tumorous bladder proliferation on both ostii in a
young patient after MUD-PBSCT, successfully treated with
operative incision and DJ catheter.
References
[1] S. D. Gardner, A. M. Field, D. V. Coleman, and B. Hulme,
“New human papovavirus (B.K.) isolated from urine after
renal transplantation,” Lancet, vol. 1, no. 7712, pp. 1253–1257,
1971.
[2] K. V. Shah, “Polyomavirusis,” in Fields Virology,B .N .F i e l d s ,
D. M. Knipe, and P. M. Howley, Eds., vol. 2, pp. 2027–2043,
Lippincott-Raven, Phladelphia, Pa, USA, 3rd edition, 1996.
[ 3 ]M .D .R e p l o e g ,G .A .S t o r c h ,a n dD .B .C l i ﬀord, “BK virus: a
clinical review,” Clinical Infectious Diseases,v o l .3 3 ,n o .2 ,p p .
191–202, 2001.
[4] H. J. Rziha, G. W. Bornkamm, and H. Zur Hausen, “BK virus.
I. Seroepidemiologic studies and serologic response to viral
infection,”MedicalMicrobiologyandImmunology,vol.165,no.
2, pp. 73–81, 1978.
[5] T. Petrogiannis-Haliotis, G. Sakoulas, J. Kirby et al., “BK-
relatedpolyomavirusvasculopathyinarenal-transplantrecip-
ient,” New England Journal of Medicine, vol. 345, no. 17, pp.
1250–1255, 2001.
[6] K. V. Shah, “Human polyomavirus BKV and renal disease,”
Nephrology Dialysis Transplantation, vol. 15, no. 6, pp. 754–
755, 2000.
[7] H. H. Hirsch, D. C. Brennan, C. B. Drachenberg et al.,
“Polyomavirus-associated nephropathy in renal transplanta-
tion: interdisciplinary analyses and recommendations,” Trans-
plantation, vol. 79, no. 10, pp. 1277–1286, 2005.
[ 8 ]C .B .D r a c h e n b e r g ,J .C .P a p a d i m i t r i o u ,H .H .H i r s c he ta l . ,
“Histological patterns of polyomavirus nephropathy: correla-
tion with graft outcome and viral load,” American Journal of
Transplantation, vol. 4, no. 12, pp. 2082–2092, 2004.
[9] R. R. Arthur, K. V. Shah, and S. J. Baust, “Association of BK
viruriawithhemorrhagiccystitisinrecipientsofbonemarrow
transplants,” New England Journal of Medicine, vol. 315, no. 4,
pp. 230–234, 1986.
[10] H. H. Hirsch and J. Steiger, “Polyomavirus BK,” Lancet
Infectious Diseases, vol. 3, no. 10, pp. 611–623, 2003.
[11] A. Bedi, C. B. Miller, J. L. Hanson et al., “Association of BK
virus with failure of prophylaxis against hemorrhagic cystitis
following bone marrow transplantation,” Journal of Clinical
Oncology, vol. 13, no. 5, pp. 1103–1109, 1995.
[12] A. Azzi, S. Cesaro, D. Laszlo et al., “Human polyomavirus
BK (BKV) load and haemorrhagic cystitis in bone marrow
transplantation patients,” Journal of Clinical Virology, vol. 14,
no. 2, pp. 79–86, 1999.
[13] H. M. Kantarjian, S. O’Brien, T. L. Smith et al., “Results
of treatment with hyper-CVAD, a dose-intensive regimen,
in adult acute lymphocytic leukemia,” Journal of Clinical
Oncology, vol. 18, no. 3, pp. 547–561, 2000.
[14] European Leukemia Net: European Trial Registry-Trial:
ALL GMALL 07/2003, http://www.leukemia-net.org/content/
leukemias/all/all trials/database.
[15] M. A. van Gorder, P. D. Pelle, J. W. Henson, D. H. Sachs,
A. B. Cosimi, and R. B. Colvin, “Cynomolgus polyoma virus
infection. A new member of the polyoma virus family causes
interstitial nephritis, ureteritis, and enteritis in immunosup-
pressed cynomolgus monkeys,” American Journal of Pathology,
vol. 154, no. 4, pp. 1273–1284, 1999.
[16] P. Brousset, V. de Araujo, and R. D. Gascoyne, “Immunohisto-
chemicalinvestigationofSV40largeTantigeninHodgkinand
non-Hodgkin’s lymphoma,” International Journal of Cancer,
vol. 112, no. 3, pp. 533–535, 2004.
[17] D. M. Whiley, I. M. Mackay, and T. P. Sloots, “Detection
and diﬀerentiation of human polyomaviruses JC and BK by
LightCycler PCR,” Journal of Clinical Microbiology, vol. 39, no.
12, pp. 4357–4361, 2001.
[ 1 8 ]H .H .H i r s c h ,M .M o h a u p t ,T .K l i m k a i t ,A .P .L i m a y e ,a n d
K. R. Jerome, “Prospective monitoring of BK virus load after
discontinuingsirolimustreatmentinarenaltransplantpatient
with BK virus nephropathy [1] (multiple letters),” Journal of
Infectious Diseases, vol. 184, no. 11, pp. 1494–1496, 2001.
[19] D. Geetha, B. C. Tong, L. Racusen, J. S. Markowitz, and
W. H. Westra, “Bladder carcinoma in a transplant recipient:
evidence to implicate the BK human polyomavirus as a causal
transforming agent,” Transplantation, vol. 73, no. 12, pp.
1933–1936, 2002.
[20] H. H. Hirsch, “BK virus: opportunity makes a pathogen,”
Clinical Infectious Diseases, vol. 41, no. 3, pp. 354–360, 2005.
[21] P.H.O’Donnell,K.Swanson,M.A.Josephsonetal.,“BKvirus
infection is associated with hematuria and renal impairment
in recipients of allogeneic hematopoetic stem cell transplants,”
Biology of Blood and Marrow Transplantation, vol. 15, no. 9,
pp. 1038–1048, 2009.6 Journal of Transplantation
[22] H.H.Hirsch,W.Knowles,M.Dickenmannetal.,“Prospective
studyofpolyomavirustypeBKreplicationandnephropathyin
renal-transplant recipients,” New England Journal of Medicine,
vol. 347, no. 7, pp. 488–496, 2002.
[ 2 3 ]C .H a r k e n s e e ,N .V a s d e v ,A .R .G e n n e r y ,I .E .W i l l e t t s ,a n dC .
Taylor, “Prevention and management of BK-virus associated
haemorrhagic cystitis in children following haematopoietic
stem cell transplantation—a systematic review and evidence-
based guidance for clinical management,” British Journal of
Haematology, vol. 142, no. 5, pp. 717–731, 2008.
[24] L. K. Dropulic and R. J. Jones, “Polyomavirus BK infection
in blood and marrow transplant recipients,” Bone Marrow
Transplantation, vol. 41, no. 1, pp. 11–18, 2008.
[25] G. A. Weinberg and A. N. Mian, “BK virus nepropathy
and other polyoma virus infections,” The Pediatric Infestions
Disease Journal, vol. 29, pp. 257–260, 2010.
[26] A. Vats, R. Shapiro, P. S. Randhawa et al., “Quantitative viral
load monitoring and cidofovir therapy for the management
of BK virus-associated nephropathy in children and adults,”
Transplantation, vol. 75, no. 1, pp. 105–112, 2003.